These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 20181452

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A.
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [Abstract] [Full Text] [Related]

  • 3. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME, Reilly LM, Gerami P, Guitart J.
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [Abstract] [Full Text] [Related]

  • 4. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L, Li P, Lin XJ, Yuan YF, Zhang YQ, Chen MS.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
    Sibaud V, Delord JP, Chevreau C.
    Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
    [Abstract] [Full Text] [Related]

  • 7. [Sorafenib(Nexavar)].
    Miyanaga N, Akaza H.
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
    [Abstract] [Full Text] [Related]

  • 8. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA, Goldspiel BR.
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib.
    Hasskarl J.
    Recent Results Cancer Res; 2010 Aug; 184():61-70. PubMed ID: 20072831
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B, Di Maio M.
    J Clin Gastroenterol; 2009 Aug; 43(5):389-90. PubMed ID: 19564813
    [No Abstract] [Full Text] [Related]

  • 18. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J.
    Klin Onkol; 2012 Aug; 25(4):287-9. PubMed ID: 22920170
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.